Thus, even though multiple studies have concluded that TLR7 agonists in combination with cancer vaccines are safe and supports antigen-specific responses, optimization of dosing and timing for this class of vaccine adjuvant appears necessary. The gene discussed is TLR7; the disease is cancer.